Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 9;78(19):e163-e164.
doi: 10.1016/j.jacc.2021.08.054.

Racial and Ethnic Representation in Atrial Fibrillation Trials: CABANA and Beyond

Tarryn Tertulien, Jared W Magnani, Utibe R Essien
Comment

Racial and Ethnic Representation in Atrial Fibrillation Trials: CABANA and Beyond

Tarryn Tertulien et al. J Am Coll Cardiol. .
No abstract available

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1. Racial/Ethnic Representation in Clinical Trials and Observational Studies of Atrial Fibrillation
Proportion of White versus racial/ethnic minorities in clinical trials and observational studies of atrial fibrillation. ACTIVE-A = Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events; ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; AUGUSTUS = The Open-Label, 2 × 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Trial; AVERROES = Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment Trial; BRIDGE = Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery Trial; CABANA = Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial; EMANATE = Eliquis evaluated in acute cardioversion coMpared to usual treatmeNts for AnticoagulaTion in subjEcts with atrial fibrillation Trial; ENGAGE AF-TIMI 48 = Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48; PREVAIL = Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation; RE-DUAL PCI = Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Trial; RE-LY = Randomized Evaluation of Long-Term Anticoagulation Therapy. Reprinted with permission from Essien et al (4).
See this image and copyright information in PMC

Comment on

References

    1. Thomas KL, Al-Khalidi HR, Silverstein AP, et al. Ablation versus drug therapy for atrial fibrillation in racial and ethnic minorities. J Am Coll Cardiol. 2021;78:126–138. - PMC - PubMed
    1. Magnani JW, Norby FL, Agarwal SK, et al. Racial differences in atrial fibrillation-related cardiovascular disease and mortality. JAMA Cardiol. 2016;1: 433–441. - PMC - PubMed
    1. U.S. Census Bureau (2016). State and County QuickFacts. Accessed September 27, 2021. https://www.census.gov/quickfacts/fact/table/US/PST045219
    1. Essien UR, Kornej J, Johnson AE, Schulson LB, Benjamin EJ, Magnani JW. Social determinants of atrial fibrillation. Nat Rev Cardiol. 2021;18:763–773. - PMC - PubMed
    1. Brewer LC, Pasha M, Seele P, et al. Overcoming historical barriers: enhancing positive perceptions of medical research among African Americans through a conference-based workshop. J Gen Intern Med. 2021;36:2547–2554. - PMC - PubMed

Publication types